130 related articles for article (PubMed ID: 29807678)
21. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
Wu Y; Li P; Zhang H; Shi Y; Wu H; Zhang J; Qian Y; Li C; Yang J
Int J Cancer; 2013 Jan; 132(2):E37-47. PubMed ID: 22890912
[TBL] [Abstract][Full Text] [Related]
23. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
Guan Y; He S; Dong J
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
[TBL] [Abstract][Full Text] [Related]
24. Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.
Marquez-Medina D; Martin-Marco A; Popat S
Clin Transl Oncol; 2016 Feb; 18(2):228-32. PubMed ID: 26203801
[TBL] [Abstract][Full Text] [Related]
25. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
26. Imaging in lung cancer: positron emission tomography scan.
Vansteenkiste JF
Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
28. Information feedback of
Mu Y; Gui J; Lang Z; Ren C; Yan L; Liu H; Liang J; Feng H
J Infect Public Health; 2020 Sep; 13(9):1336-1341. PubMed ID: 31289004
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of metabolic tumor volume of pretreatment
Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
[TBL] [Abstract][Full Text] [Related]
30. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
31. Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
Schoenmaekers J; Hofman P; Bootsma G; Westenend M; de Booij M; Schreurs W; Houben R; De Ruysscher D; Dingemans AM; Hendriks LEL
Eur J Cancer; 2019 Jul; 115():88-96. PubMed ID: 31129385
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
Wu H; Dong S; Li X; Shi L; Shao D; Zhang Q; Chen M; Cao Y; Thant M; Huang X
Lung Cancer; 2020 Feb; 140():80-86. PubMed ID: 31901595
[TBL] [Abstract][Full Text] [Related]
33. [Role of FDG-PET scanning in stage IIIAN2 non-small cell lung cancer].
Colavolpe C; Bonardel G; Guedj E; Cammilleri S; Mundler O; Barlesi F
Rev Mal Respir; 2012 Feb; 29(2):149-60. PubMed ID: 22405110
[TBL] [Abstract][Full Text] [Related]
34. Positron emission tomography (PET) and combined imaging modalities for staging lung cancer.
Scott WJ
Surg Clin North Am; 2002 Jun; 82(3):477-95. PubMed ID: 12371581
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performance of different imaging modalities in the assessment of distant metastasis and local recurrence of tumor in patients with non-small cell lung cancer.
Ohno Y; Yoshikawa T; Kishida Y; Seki S; Koyama H; Yui M; Kassai Y; Aoyagi K; Kaminaga S; Sugimura K
J Magn Reson Imaging; 2017 Dec; 46(6):1707-1717. PubMed ID: 28419645
[TBL] [Abstract][Full Text] [Related]
36. Segmentation in Non-Small Cell Lung Tumors Using 18F-FDG PET/CT: Tips and Rules.
Jiménez Londoño GA; Pérez-Beteta J; Bosque JJ; Honguero-Martinez AF; García Vicente AM
Clin Nucl Med; 2020 Nov; 45(11):e477-e482. PubMed ID: 32701795
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
[TBL] [Abstract][Full Text] [Related]
38. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
[TBL] [Abstract][Full Text] [Related]
39. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
[TBL] [Abstract][Full Text] [Related]
40. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
